1. Real-life data of major and minor bleeding events with direct oral anticoagulants in the one-year follow-up period: The NOAC-TURK study
- Author
-
Lütfü Aşkın, Mahmut Şahin, Ahmet Yanık, Serkan Ünlü, Uğur Canpolat, Ümit Yaşar Sinan, Feyzullah Besli, Seçkin Pehlivanoğlu, Ömer Gedikli, Huseyin Altug Cakmak, and Servet Altay
- Subjects
Adult ,medicine.medical_specialty ,One year follow up ,Adolescent ,Pyridones ,Administration, Oral ,Hemorrhage ,Dabigatran ,Rivaroxaban ,Internal medicine ,Atrial Fibrillation ,medicine ,Diseases of the circulatory (Cardiovascular) system ,Humans ,In patient ,cardiovascular diseases ,Prospective Studies ,Prospective cohort study ,Original Investigation ,Aged ,Aged, 80 and over ,business.industry ,Anticoagulants ,Atrial fibrillation ,Middle Aged ,medicine.disease ,Real life data ,Stroke ,RC666-701 ,cardiovascular system ,Apixaban ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug ,Follow-Up Studies - Abstract
OBJECTIVE: This study aimed to evaluate the safety of direct oral anticoagulants (DOACs) in patients with non-valvular atrial fibrillation (NVAF) during daily clinical practice. METHODS: This was a prospective study conducted between January 01, 2016, and April 01, 2017, in patients aged ≥18 years with a diagnosis of NVAF. We performed the study in 9 clinical centers from different regions of Turkey, and the mean follow-up period was 12+2 months. We investigated major and minor bleeding events of DOAC. RESULTS: A total of 1807 patients with NVAF were enrolled. The mean age of the patients was 73.6±10.2 years, CHA2DS2-VASc score was 3.6±1.4, and HAS-BLED score was 2±1.2. The most frequently prescribed DOAC was dabigatran 110 mg bid in 409 (22.6%) patients. The patients on apixaban 2.5 mg bid were older (p
- Published
- 2021